David Mathai MD
Psychopharmacology, Integrative Psychiatry, Clinical Pharmacology
Assistant Professor at Baylor College of Medicine
Join to View Full Profile
20200 West Dixie Highway Suite 902Aventura, FL 33180
Phone+1 561-570-2031
Dr. Mathai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Mathai is a board-certified psychiatrist with Sattva Medicine PLLC and an Assistant Professor at Baylor College of Medicine. He completed advanced pharmacology research training as a postdoctoral fellow with the Johns Hopkins Center for Psychedelic and Consciousness Research.
Education & Training
Johns Hopkins UniversityFellowship, Research, 2021 - 2023
Baylor College of MedicineResidency, Psychiatry, 2017 - 2021- Baylor College of MedicineClass of 2017
Certifications & Licensure
FL State Medical License 2023 - 2027
MD State Medical License 2021 - 2025
TX State Medical License 2024 - 2025
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use.David S Mathai, Daniel E Roberts, Sandeep M Nayak, Nathan D Sepeda, Amy Lehrner
Journal of Psychoactive Drugs. 2025-02-07 - On Minimizing Risk and Harm in the Use of Psychedelics.Jules Evans, Marc Aixalà, Brian T Anderson, William Brennan, Rebecka Bremler
Psychiatric Research and Clinical Practice. 2025-01-01 - 1 citationsKnowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.Erin Wang, David S Mathai, Natalie Gukasyan, Sandeep Nayak, Albert Garcia-Romeu
Scientific Reports. 2024-11-14
Press Mentions
Psychedelics: A Unique Psychiatric ParadigmJune 3rd, 2023
What the (second) wave of psychedelics research could mean for mental healthMay 30th, 2023
Ketamine no better than placebo at alleviating depressionMay 18th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
